By proceeding, you agree to our Terms of Use and Privacy Policy.
Principal Toxicologist
#organicsynthesis #hplc #massspectrometry
#NorthAmerica
Multi-step organic synthesis, process chemistry, peptide chemistry, palladium mediated cross-coupling, technology transfer and out licensing, drug discovery, structure-based drug design, fragment and
Associate Director
#oligonucleotidesdrugdevelopment #massspectrometry
Pragmatic pharmaceutical dev. & mfg. leader with strength in oligonucleotide, small molecule, and protein analyses. Extensive knowledge of developing phase appropriate control strategies, supporting C
Assistant Professor
#MassSpectrometry #AnalyticalChemistry #Leadership
I am a postdoctoral fellow within the analytical chemistry division. I aspire to be in an academic position where I can help encourage and inspire students to persist towards a graduate degree within
Principal Scientist
#MassSpectrometry #Microfluidics #Biochemistry #AssayDevelopment
Jeffrey Martin is actively involved in groundbreaking research with a focus on XPO1, a therapeutic target with implications in both oncology and amyotrophic lateral sclerosis (ALS). His work centers o
Global Head of Lead Evalution and Protein Science
#proteinpurification #massspectrometry
#Northamerica
Qian Zhang is currently working as Global Head of Lead Evalution and Protein Science at HiFiBio Therapeutics
Department Head
#impuritiesindrugs #massspectrometry #research
#Europe
Rok Grahek received his B. Sc in Chemistry and his Ph.D. in Science from the University of Ljubljana, Slovenia.In 1986 Rok was employed in Research and development in Lek Pharmaceuticals d.d.. Sloveni
Senior Scientist Structure Elucidation
#nmrspectroscopy #massspectrometry #structureelucidation
Ruth Boetzel is currently Senior Principal Scientist Structure Elucidation at Pfizer,Extensive experience in NMR spectroscopy of small molecules and proteins,Structure elucidation of small molecules b
Vice President, Cell Therapy CMC
#hplc #massspectrometry
Experienced Vice President with a passion for science and people and to drive projects and technologies forward for the benefit of patients with unmet medical needs. I have a demonstrated history of w